HomeGeneticsConditionChildhood myocerebrohepatopathy spectrum
Back to Condition
Childhood myocerebrohepatopathy spectrum
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Childhood myocerebrohepatopathy spectrum

Childhood myocerebrohepatopathy spectrum (MCHS) is a POLG-related disorder characterized by muscle, nerve, and brain-related dysfunction, typically appearing between infancy and age 3.

Overview

MCHS affects the muscles (myo-), brain (cerebro-), and liver (hepato-). It is part of a group of conditions caused by mutations in the POLG gene.

Symptoms

  • Muscle weakness (myopathy)
  • Developmental delay or deterioration of intellectual function
  • Liver disease
  • Toxic buildup of lactic acid (lactic acidosis)
  • Failure to thrive (inability to gain weight and grow at the expected rate)
  • Renal tubular acidosis (a form of kidney disease)
  • Inflammation of the pancreas (pancreatitis)
  • Cyclic vomiting (recurrent episodes of nausea and vomiting)
  • Hearing loss

Causes

MCHS is caused by mutations in the POLG gene, which provides instructions for the alpha subunit of a protein called polymerase gamma (pol γ).

  • Pol γ is essential for the replication of mitochondrial DNA (mtDNA) within mitochondria, the structures that convert energy from food into a form cells can use.
  • Mutations in the POLG gene often result in fewer copies of mtDNA (mtDNA depletion), particularly in muscle, brain, or liver cells.
  • This depletion causes a decrease in cellular energy, which accounts for the signs and symptoms of the condition.

Inheritance

This condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene but typically do not show signs or symptoms of the condition.

Frequently Asked Questions

Immediate management includes intravenous bicarbonate to correct severe acidosis, careful fluid balance to avoid worsening hepatic encephalopathy, and avoidance of mitochondrial toxins (e.g., valproic acid, certain antibiotics). Consultation with a metabolic specialist is essential; some centers use dichloroacetate or thiamine trials, though evidence is limited.
Look for a combination of unexplained muscle weakness or hypotonia, poor feeding with failure to thrive, episodes of vomiting or cyclic vomiting, and early developmental delay. Laboratory clues such as elevated lactate, transaminases, or evidence of renal tubular acidosis strengthen suspicion and should trigger genetic testing for POLG mutations.
Diagnosis relies on molecular analysis of the POLG gene. Blood DNA is the first step; if results are inconclusive, skin fibroblast or muscle biopsy can be used for more sensitive detection of mtDNA depletion. Enzyme studies are not required, but baseline labs (lactate, liver panel, renal function, CK) help assess disease burden.
Yes. Because MCHS is autosomal recessive, each sibling of an affected child has a 25 % chance of being affected, a 50 % chance of being an asymptomatic carrier, and a 25 % chance of inheriting two normal alleles. Prenatal testing or pre‑implantation genetic diagnosis is possible if the specific POLG mutations are known.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss